Translational research progress in inhibitory effect of EGFR targeting small molecular inhibitor Tarceva on tumor cells
10.3760/cma.j.issn.1673-422X.2010.07.012
- VernacularTitle:表皮生长因子受体小分子抑制剂埃罗替尼应用研究进展
- Author:
Jun LIU
- Publication Type:Journal Article
- Keywords:
Receptor,epidermal growth factor;
Neoplasms;
Erlotinib
- From:
Journal of International Oncology
2010;37(7):517-520
- CountryChina
- Language:Chinese
-
Abstract:
Large quantities of recent researches show abnormal expression of epidermal growth factor receptor (EGFR)in different solid tumors. An especial relationship between EGFR expression and tumor cell proliferation, angiogenesis, invasive ability metastasis and apoptosis has been established. Tarceva, is an epidermal growth factor tyrosine kinase reversible inhibitor, which blocks signal transduction by inhibiting the tyrosine kinase phosphorylation and thus inhibits tumor growth. Tarceva is now proved to have certain therapeutic effects on non-small cell lung carcinoma ( NSCLC ), however, it has not shown a convincing effect when applied in gli omas and other tumors. Now the research of the combination with Tarceva and other anti-tumor drugs has come into the focus. Combination therapy with Tarceva and other chemotherapeutic drugs or other means might be an effective alternative.
